Sanofi has again called on investment bankers at the independent advisory firm Lazard, as the French healthcare group works on pushing through two deals worth more than $16bn.

Sanofi said in a statement this morning that it had agreed a deal worth around €3.9bn ($4.8bn) to acquire Belgium-headquarted Ablynx, a pharmaceutical company that develops nanobodies.